<code id='8146A4CC30'></code><style id='8146A4CC30'></style>
    • <acronym id='8146A4CC30'></acronym>
      <center id='8146A4CC30'><center id='8146A4CC30'><tfoot id='8146A4CC30'></tfoot></center><abbr id='8146A4CC30'><dir id='8146A4CC30'><tfoot id='8146A4CC30'></tfoot><noframes id='8146A4CC30'>

    • <optgroup id='8146A4CC30'><strike id='8146A4CC30'><sup id='8146A4CC30'></sup></strike><code id='8146A4CC30'></code></optgroup>
        1. <b id='8146A4CC30'><label id='8146A4CC30'><select id='8146A4CC30'><dt id='8146A4CC30'><span id='8146A4CC30'></span></dt></select></label></b><u id='8146A4CC30'></u>
          <i id='8146A4CC30'><strike id='8146A4CC30'><tt id='8146A4CC30'><pre id='8146A4CC30'></pre></tt></strike></i>

          Home / knowledge / focus

          focus


          focus

          author:focus    Page View:88
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In